|
Jul 31
|
Evotec SE's (ETR:EVT) largest shareholders are retail investors with 48% ownership, institutions own 36%
|
|
Jun 12
|
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
|
|
May 22
|
Evotec Reports Q1 2024 Results and Provides Corporate Update
|
|
Apr 18
|
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
|
|
Apr 17
|
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
|
|
Apr 17
|
Evotec welcomes Aurélie Dalbiez as Chief People Officer
|
|
Feb 15
|
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.
|
|
Jan 10
|
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
|
|
Jan 8
|
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
|
|
Jan 4
|
Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
|
|
Jan 3
|
Evotec Announces CEO Transition
|
|
Dec 19
|
Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes
|
|
Dec 14
|
Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases
|
|
Dec 6
|
Evotec-partner Jingxin Receives Approval for EVT201 in China
|
|
Dec 4
|
Evotec SE's (ETR:EVT) largest shareholders are individual investors with 47% ownership, institutions own 34%
|
|
Dec 1
|
‘From Hype to Clinical‘: Cowen Suggests 2 AI Healthcare Stocks to Consider
|
|
Nov 15
|
Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day
|
|
Jun 29
|
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
|